# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of ...
JP Morgan analyst Brian Cheng upgrades Mersana Therapeutics (NASDAQ:MRSN) from Underweight to Neutral and announces $5 price...
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed four...
U.S. stocks were higher, with the Nasdaq Composite gaining around 50 points on Thursday.